1. Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population.
- Author
-
Sosolik RC, Hitchcock CL, and Becker WJ
- Subjects
- Animals, Antibodies, Heterophile administration & dosage, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Blood Protein Electrophoresis, Carcinoma therapy, Colorectal Neoplasms therapy, Enzyme-Linked Immunosorbent Assay, False Positive Reactions, Humans, Isoenzymes, Mice, Myocardial Ischemia enzymology, Predictive Value of Tests, Antibodies, Heterophile therapeutic use, Antigens, Neoplasm immunology, Carcinoma enzymology, Colorectal Neoplasms enzymology, Creatine Kinase blood, Glycoproteins immunology
- Abstract
Dual-site murine antibody-based immunoassays are commonly used in clinical laboratories to quantitate the MB isoenzyme of creatine kinase (CK-MB). Because the serum level of CK-MB is a relatively specific and sensitive indicator of myocardial ischemic damage, accurate quantitation is essential for a correct diagnosis. Heterophile antibodies (eg, human anti-murine antibodies) can interfere with these assays, however, and produce erroneous results. A subpopulation of 19 surgical patients with colorectal carcinoma who had received injections of an 125I-labeled murine monoclonal antibody directed against a tumor-associated glycoprotein was studied. Serum specimens from eight patients (42%) showed a marked increase in the level of CK-MB and normal total CK concentrations. The increased concentrations of CK-MB, which were attributed to interference by human antimurine antibodies, were substantially reduced in these specimens after a heterophile blocking reagent was added. However, this reagent did not significantly alter the serum level of CK-MB in patients who had clinical evidence of acute myocardial ischemia.
- Published
- 1997
- Full Text
- View/download PDF